A Study of Patients With Chronic Disease

Target PharmaSolutions

Status: Active, not recruiting

Conditions: Asthma; Respiratory Disease; IPF; Chronic Obstructive Pulmonary Disease; COPD; Idiopathic Pulmonary Fibrosis

Study type: Observational

Funder types: Industry

Identifiers

NCT04263727

TARGET-RWE

Details and patient eligibility

About

TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.

Full description

The TARGET-RWE master protocol design allows shared study parameters and operational components to be organized within a centralized platform. Utilizing this platform, therapeutic area-aligned Communities with associated Disease-Specific Cohorts (DSC) can be added according to scientific merit and need to address specific research questions in patients diagnosed with chronic diseases. This design capitalizes on a shared, sustainable infrastructure across a diverse patient population, which allows for more efficient coordination and conduct than can be achieved in traditional stand-alone, independently-conducted research studies with narrowly-focused target patient populations. This master protocol design will ultimately support a dynamic program that adapts to the changing landscape of chronic disease management and allows for rapid enrollment and collection of retrospective and long-term prospective data from participants in specific disease areas of interest.

TARGET-RWE currently includes the TARGET-RWE.LUNG Community, with open DSCs for Asthma, COPD and Idiopathic Pulmonary Fibrosis.

Enrollment: 100,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults and children being managed or treated for a chronic disease under study. Diagnosis is based on the clinical judgement of the care provider.
• Patient is anticipated to have continued management of their chronic disease at the participating site.

Exclusion criteria

• Inability to provide informed assent/consent.

Trial design

100,000 participants in 3 patient groups

Asthma

Description:

Non-Interventional. Patients with asthma will be screened and enrolled into the active Asthma disease-specific cohort.

Chronic Obstructive Pulmonary Disease (COPD)

Description:

Non-Interventional. Patients with COPD will be screened into the inactive COPD disease-specific cohort.

Idiopathic Pulmonary Fibrosis (IPF)

Description:

Non-Interventional. Patients with IPF will be screened into the inactive IPF disease-specific cohort.